autologous blood and marrow transplantation - Blog Science ...

Table 2. Patient characteristics, group B
Total
Histologic subtype (WF)
Low grade
Intermediate grade
High grade
Lymphoblastic
Burkitt's/Burkitt-like
Source of stem cells
Bone marrow
Peripheral blood
Both
Allogeneic
High dose regimen
Chemotherapy only
Chemotherapy + TBI
Sweetenham et al.
Statistical analysis
Number (%)
1339 (100)
187 (14.0)
393 (29.4)
439 (32.8)
245 (18.3)
75 (5.6)
753 (56.2)
420(31.4)
61 (4.6)
105 (7.8)
743 (55.5)
596 (44.5)
Survival analyses were performed according to the method of Kaplan and
Meier. 8
Overall survival was calculated from the date of stem cell reinfusion or the
date of relapse/progression to the date of death from any cause. Time to
relapse/progression was calculated from the date of stem cell reinfusion until the
date of documented disease relapse or progression.
RESULTS
Group A
Of the 106 patients undergoing high-dose therapy, 103 achieved a partial or
complete response. Two patients had progressive disease, and there was one
treatment-related death at day 10 after autologous stem cell reinfusion from
pulmonary hemorrhage. Of the 103 responding patients, 57 have relapsed. The
median time to relapse was 9 months after autoSCT. The actuarial overall survival
from the date of autologous stem cell reinfusion is shown in Fig. 1A and the failure-
free survival in Fig. IB. The median time to relapse for the entire population was
9 months.
Sites of relapse are summarized in Table 3. Most relapses (63%) occurred in local
or locoregional sites in this group of patients with predominantly diffuse large B cell
lymphoma. The remaining relapses were at distant sites only, or a combination of
171